Retinal Vein Occlusion Market Size Worth $25.8 Billion By 2030 | CAGR: 8.8%

Retinal Vein Occlusion Market Size Worth $25.8 Billion By 2030 | CAGR: 8.8%

The global retinal vein occlusion market size is expected to reach USD 25.8 billion by 2030, according to a new study by Polaris Market Research. The report “Retinal Vein Occlusion Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)); By Treatment and By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.


North America controls most of the global market. It is expected to maintain its dominance in the coming years because of improved healthcare infrastructure, an increase in the prevalence of eye diseases, advanced technology, and an increase in the geriatric population.


From 2022 to 2030, the Asia Pacific is expected to grow at a rapid CAGR. Increased incidence of eye diseases in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising healthcare expenditure, are expected to drive market growth in Asia Pacific.


Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:


As there is no scientifically proven treatment for long-term vision loss, the current RVO treatment option is to minimize the damage. This treatment aims to prevent further vision loss and complications caused by macular edema, ischemia, or neovascularization. The use of anti-VEGF injection completely prevents the growth of new blood vessels in the eye, which causes Glaucoma.


The increased geriatric population with eye disease, as well as the rise in ophthalmic disease globally, may have an impact on the growth of the market. The market is growing due to an increase in eye diseases worldwide, an increase in the geriatric population, and an increase in awareness about eye disease. However, the side effects of are expected to stifle the growth of the global market. Global market development is expected to increase diabetes prevalence, shift in lifestyle, and increase the occurrence of glaucoma, lymphoma, and multiple myeloma.


The rising prevalence of atherosclerosis and diabetes, recognized as the primary causes of RVO, are key factors driving the market growth. The growing patient population suffering from glaucoma, lymphoma, and myeloma is a major driver of this market. Increased research and investment by market players in developing safe and cost-effective treatments are expected to create market opportunities.


The factors driving the market are an increase in the prevalence of eye ailments such as glaucoma, a change in lifestyle, an increase in the geriatric population, and an increase in awareness about various eye disorders. Furthermore, increasing drug approval to treat RVO patients contributes to market growth.


Retinal Vein Occlusion Market Report Highlights

  • Central retinal vein occlusion segment held the largest market share as there is a rising incidence of diabetes in the population that tends to cause visual impairment.
  • Anti-VEGF held the largest treatment segment due to the growing need to cure eye diseases that cause swelling.
  • North America held the dominant position because of rising eye diseases and lifestyle disorders like diabetes that disrupt the vision in long term.
  • Major players operating in the industry include Ellex Medical Lasers, Bristol-Myers Squibb, Bayer, Allergen PLC, GlaxoSmithKline PLC, IRIDEX Corporation, Regeneron Pharmaceuticals, BioMedical Technologies, Carl Zeiss AG, NIDEK Co., LTD, Topcon Corporation.


Polaris Market Research has segmented the retinal vein occlusion market report based on disease type, treatment and region:


Retinal Vein Occlusion, Disease Type Outlook (Revenue - USD Billion, 2022 - 2030)

  • Central Retinal Vein Occlusion (CRVO)
  • Branch Retinal Vein Occlusion (BRVO)

Retinal Vein Occlusion, Treatment Outlook (Revenue - USD Billion, 2022 - 2030)

  • Anti-vascular Endothelial Growth Factor (Anti-VEGF)
  • Corticosteroid Drugs
  • Others

 Retinal Vein Occlusion, Regional Outlook (Revenue - USD Billion, 2022 - 2030)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE